After shepherding the company through its first approval and the successful launch of blockbuster autoimmune drug Vyvgart, argenx co-founder and chief executive Tim Van Hauwermeiren is passing the reins to the Dutch drugmaker’s operating chief. More: As Vyvgart empire expands,
read more
Combination therapy moves into late‑stage testing after encouraging earlier results More: HUTCHMED begins phase 3 stage of pancreatic cancer trial Source: News
read more
Company prepares regulatory filings after treatment shows significant reduction in disease flare risk More: Zenas reports strong phase 3 results for obexelimab in IgG4-related disease Source: News
read moreBausch + Lomb has partnered with the glaucoma community once again, launching its fifth annual fundraising challenge and sponsoring an awareness campaign in one of its priority therapeutic areas. More: Bausch + Lomb brings glaucoma into focus with renewed awareness
read moreA recent survey shows that healthcare professionals have varied feelings on the direct-to-patient drug sales platforms increasingly launched by pharma companies—echoing patients’ own uncertainties about the services. More: HCPs say pharmas’ direct drug sale platforms have ‘mixed’ impact on GLP-1
read moreRegardless of the year and the drug pricing landscape, the turn of the calendar always brings news of another wave of price increases. This year, pharmaceutical companies have raised the prices of more than 350 branded products, according to a
read more© 1994 - 2026 B.M. Pharmaceuticals